Chlophedianol

Summary

Chlophedianol (CHEMBL1201313) is an approved small-molecule antitussive (ATC R05DB10); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05DB10
• Indications: 1 condition
• Chemistry: 289.8 Da · C17H20ClNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201313
Name	Chlophedianol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2795
ChEBI	CHEBI:135207
ATC	R05DB10
Molecular formula	C17H20ClNO
Molecular weight	289.8
InChIKey	WRCHFMBCVFFYEQ-UHFFFAOYSA-N

SMILES: CN(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2Cl)O

IUPAC name: 1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol

ChEBI definition: A diarylmethane that is 2-chlorophenyl(phenyl)methane substituted on the methane carbon by a 2-(dimethylamino)ethyl group. Used in the treatment of dry cough, it suppresses the cough reflex by a direct effect on the cough centre in the medulla of the brain.

Pharmacological roles (ChEBI): antitussive.

Also known as: Antitussin, Clofedanol, NSC-113595, Tussistop, SID93577132, SID144206265, CHLOPHEDIANOL, clofedanol

Parent form; salt/anhydrous children: CHEMBL1200972

Patent coverage: 548 distinct patent families (1,867 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Alpha-1A adrenergic receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	5.47	AC50	3400	nM	CHEMBL_ACT_25117154
HTR2A	5.36	AC50	4400	nM	CHEMBL_ACT_25224741
OPRK1	5.15	AC50	7101	nM	CHEMBL_ACT_25129006
HTR2C	5.08	AC50	8300	nM	CHEMBL_ACT_25131346

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).